Heart Sounds Registry

To conduct a prospective, observational study to evaluate the non-interventional feasibility
of using heart sounds measurements recorded by the LifeVest® Wearable Cardioverter
Defibrillator (WCD) for monitoring clinical evidence of heart failure decompensation.

Participants will be adult (age ≥ 18 years) heart failure patients with an ejection fraction
(EF) ≤ 35% and eligible to wear the WCD for at least 3 months.

An FDA-approved WCD will be prescribed for at least 3 months of use after hospital discharge.

This is a multi-center, prospective, observational study.

The study will enroll a total of 300 subjects, anticipating that at least 250 subjects will
complete the study. A maximum of 50 sites will enroll patients into the study.

Inclusion Criteria:

- Patients who are prescribed the WCD ≤ 10 days post-discharge after hospitalization
with Heart Failure (HF), with and ischemic or non-ischemic cardiomyopathy.

- Patients who have an ejection fraction (EF) ≤ 35% at the time of WCD prescription.

- Patients are anticipated to wear the WCD for at least 3 months.

- The subject must be 18 years of age or older on the day of screening.

Exclusion Criteria:

- Patients with pacemakers, an implanted cardioverter defibrillator (ICD), or a cardiac
resynchronization therapy device.

- Patients waiting for heart transplant.

- Patients with known evidence of atrial fibrillation on their most recent ECG
recording.

- Patients currently hospitalized for acute myocardial infarction.

- Patients with a planned revascularization within 30 days of screening.

- Patients who are self-reporting to be pregnant.

- Patients participating in another clinical study.

- Patients not expected to live longer than 1 year.

- For patients in the United States, those who are unable or unwilling to provide
written informed consent in English.

- For patients in Europe, those who are unable or unwilling to provide written informed
consent in their country specific language or English.